Home Office

PPL Standard Condition 18 Notification Form

Please use this form to notify the Animals in Science Regulation Unit (ASRU) of procedural-related adverse effects that have exceeded or are likely to exceed the severity limitations or controls described in the project licence. ASRU will use this information to determine whether any further action is required.

Do not use to report:

- adverse effects that are due to non-procedural issues;
- potential non-compliance (report by other means);
- issues without adverse welfare consequences.

If you are in doubt whether or not you need to fill in this form, please contact your assigned Inspector.

Please clearly title your document: **'ASRU_establishment name_PPL number_PPLh surname_date_sc18'** and send to your Inspector (e.g. using cjsm) with the subject heading 'PPL SC 18 Notification PPL [Number] – **Check Home Office's Updated Bridging Ways of Working for updated advice on email addresses and subject headings. Cjsm no longer necessary.**

Establishment Licence name	University of Cambridge
Establishment Licence number	X81BD37B1
Name of PPL holder	Menna Clatworthy
PPL number	PD030666A
Protocol no	8
Protocol title	Infection or inoculation with pathogen or pathogen-derived molecule
Severity classification	Moderate
1. Date of incident	28/03/23

2. Species	Wild type mice
3. Brief details of study and how the limits or constraints have been breached	The aim of this study was to assess the role of immune cells in mice in response to bacteria using Staphylococcus aureus strain together with commercially available peptidoglycan in 24 hours. This protocol has a moderate severity limit, but 2 out of 3 mice died within this period.
4. Have you taken advice from the Named Animal Care and Welfare Officer/Named Veterinary Surgeon/others?	Yes, I have discussed with NACWO in our animal facility.
5. Cause of Problem, if known	I performed post mortem but there was no obvious abnormalities. Since same experiments with S.aureus alone has been done multiple times with no adverse effect, I assume that the dose of peptidoglycan was too high, although I used half of the dose reported in the literature (https://www.nature.com/articles/s41564-018-0198-3).
6. Action that has been or will be taken *(For example, formulation of drug changed, supportive treatment given, study design modified). If no action needed, indicate why (for example, none required as study has been terminated and will not be repeated)*	I will decrease the dose of peptidoglycan from 500 ug to 100 ug, an 80% reduction. I will also increase the monitoring by observing the mice twice a day after injection.
7. Reported by (name)	Tetsuo Hasegawa (PPL holder is also informed)
8. Date	28/03/23

******************************For official use**

Inspector's comments and recommendations:

Comments and recommendations	

Inspector name	
Date	